Source Newsroom: Roswell Park Cancer Institute
Newswise — BUFFALO, NY — American women of African ancestry are more likely than European Americans to have estrogen-receptor-negative (ER-negative) breast cancer. There continues to be discussion about the role of low levels of vitamin D in the development of breast cancer for these women. New research by a team from Roswell Park Cancer Institute (RPCI) and four other institutions has shown that specific genetic variations in the vitamin D receptor (VDR) and in CYP24A1 (responsible for deactivating vitamin D) are associated with an increase in breast cancer risk — particularly for ER-negative breast cancer — for African-American women.
When a team of researchers led by RPCI's Song Yao, PhD, Research Assistant Professor of Oncology, and Christine Ambrosone, PhD, Professor of Oncology and Chair of the Department of Cancer Prevention and Control, compared levels of vitamin D in the blood of women without breast cancer, they found that severe vitamin D deficiency in African-American women was almost six times more common than in European-American women. However, because low levels of vitamin D can also be caused by disease, or by treatment, the researchers decided to focus their studies on genetic variations in VDR and the enzymes responsible for breaking down vitamin D in the body.
The results, published in BioMed Central's open-access journal Breast Cancer Research, showed that African-American women with the highest levels of vitamin D also had a specific variation in VDR. Although this variation was present in European Americans, it was not associated with alteration in their levels of vitamin D. African-American women with the specific variation associated with the higher levels of vitamin D had half the risk of breast cancer compared to women without it.
When the researchers looked in detail at the patterns of genetic variation for women with ER-negative breast cancer, they found that seven SNPs in the gene coding for CYP24A1 were associated with ER-negative breast cancer risk, and that two of these seemed to account for the higher risk of ER-negative breast cancer in African-American women.
"While it is difficult to determine the exact effect of low levels of vitamin D on the risk of developing breast cancer," said Dr. Yao, "our results show that these genetic variations, which contribute to the function of vitamin D, are strongly associated with ER-negative breast cancer and may contribute to the more aggressive breast cancer features seen in African-American women."
Co-authors included researchers from the University of Pittsburgh Cancer Institute, Mount Sinai School of Medicine, New Jersey State Cancer Registry, and The Cancer Institute of New Jersey at the Robert Wood Johnson Medical School.
The abstract of the study, "Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study," is available at http://breast-cancer-research.com/content/14/2/R58/abstract; full article available on request.
Breast Cancer Research is an international peer-reviewed online journal publishing original research, reviews, commentaries and reports. BioMed Central (http://www.biomedcentral.com/) is an STM (science, technology and medicine) publisher that has pioneered the open-access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email firstname.lastname@example.org.